Cat. #154753
Anti-CD6 [SPVL14]
Cat. #: 154753
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: CD6
Class: Monoclonal
Application: FACS ; IHC ; IF ; IP
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Netherlands Cancer Institute
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-CD6 [SPVL14]
- Alternate name: TP12
- Research fields: Cell signaling and signal transduction;Immunology
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 150 kDa
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IHC ; IF ; IP
- Description: CD6 encodes a protein found on the outer membrane of T-lymphocytes as well as some other immune cells. The encoded protein contains three scavenger receptor cysteine-rich (SRCR) domains and a binding site for an activated leukocyte cell adhesion molecule. The gene product is important for continuation of T cell activation
- Immunogen: Cloned cytotoxic T lymphocytes.
- Isotype: IgG1
- Myeloma used: Sp2/0-Ag14
Target Details
- Target: CD6
- Molecular weight: 150 kDa
- Target background: CD6 encodes a protein found on the outer membrane of T-lymphocytes as well as some other immune cells. The encoded protein contains three scavenger receptor cysteine-rich (SRCR) domains and a binding site for an activated leukocyte cell adhesion molecule. The gene product is important for continuation of T cell activation
Applications
- Application: FACS ; IHC ; IF ; IP
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- Yssel et al. 1987. Cell Immunol. 105(1):161-73. PMID: 3545502.
